Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Daiichi Sankyo
Chubb
Healthtrust
McKesson
Queensland Health

Generated: August 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,906,342

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,906,342
Title:Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
Abstract: Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.
Inventor(s): Roder; Heinrich (Steamboat Springs, CO), Tsypin; Maxim (Steamboat Springs, CO), Grigorieva; Julia (Steamboat Springs, CO)
Assignee: Biodesix, Inc. (Steamboat Springs, CO)
Application Number:12/584,594
Patent Claims:1. A method of facilitating treatment of a non-small cell lung cancer (NSCLC) comprising the steps of: 1) assigning a baseline class label for the patient using a classifier operating on integrated intensity values at pre-defined m/z ranges in mass-spectral data obtained from a blood-based sample of the patient and a training set comprising class-labeled spectra from other patients, the baseline class label indicating whether the patient is likely to benefit from administration of a drug targeting an epidermal growth factor receptor pathway, wherein if the baseline class label is "good" (or the equivalent), the drug is administered to the patient; and 2) thereafter, while the patient is being treated with the drug, a) obtaining a mass spectrum of a blood-based sample of the patient, b) performing one or more predefined pre-processing steps on the mass spectrum, c) obtaining integrated intensity values of selected features in said spectrum at said one or more predefined m/z ranges after the pre-processing steps on the mass spectrum have been performed, and d) assigning a further class label for the sample using the classifier and the training set, the further class label indicating whether the patient has developed a non-responsiveness to the treatment with the said drug wherein the drug is selected from the group of drugs consisting of gefitinib or equivalent thereof; erlotinib or equivalent thereof and cetuximab or equivalent thereof.

2. The method of claim 1, wherein the patient is a male smoker or male ex-smoker.

3. The method of claim 1, wherein step 2) including sub-steps a)-d) are performed periodically during the course of treatment of the patient.

Details for Patent 7,906,342

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial Biodesix, Inc. (Steamboat Springs, CO) 2026-03-31 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 7,906,342

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2007126758 Jan 10, 2008
World Intellectual Property Organization (WIPO) 2007126758 Nov 08, 2007
World Intellectual Property Organization (WIPO) 2010085234 Jul 29, 2010
World Intellectual Property Organization (WIPO) 2010085235 Jul 29, 2010
United States of America 2007231921 Oct 04, 2007
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Deloitte
Baxter
Teva
Queensland Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.